SENSEX 76059.77 (-0.43)

Nifty 50 23767.45 (-0.43)

Nifty Bank 56693.5 (0.18)

Nifty IT 28767.95 (0.82)

Nifty Midcap 100 61622.35 (-0.10)

Nifty Next 50 71766 (-0.10)

Nifty Pharma 25548.15 (-0.41)

Nifty Smallcap 100 18874.95 (-0.32)

Indian Market
Nifty 50 48,450.45 +541.45 | 0.85%
Nifty 100 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
Global Market
Nifty 50 48,450.45 +541.45 | 0.85%
Nifty 100 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
Sensex 48,450.45 +541.45 | 0.85%
News
  • Investment Services
  • Empower your investments with real-time data and personalized strategies. Join us at JustTrade and shape your
  • Investment Services
  • Empower your investments with real-time data and personalized strategies. Join us at JustTrade and shape your
  • Investment Services
  • Empower your investments with real-time data and personalized strategies. Join us at JustTrade and shape your
Alkem launches semaglutide in ready-to-use single-shot pre-filled syringes
(18:20, 02 Jun 2026)
Alkem Laboratories announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths at price starting Rs 350.

Alkem is the first company in India to introduce semaglutide in single-shot pre-filled syringe format, expanding treatment options for patients and lowering entry barriers with its affordable pricing. The ready-to-use single shot pre-filled syringe format offers enhanced access, and convenience.

The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.

In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable injection pens format in the Indian market. The company has also received regulatory approval for semaglutide vials, which will be launched soon.